Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
|
|
15.
|
|
|
16.
|
|
|
17.
|
|
|
18.
|
|
|
19.
|
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. [electronic resource] by
- Jung, Kyung Hae
- Ataseven, Beyhan
- Verrill, Mark
- Pivot, Xavier
- De Laurentiis, Michelino
- Al-Sakaff, Nedal
- Lauer, Sabine
- Shing, Mona
- Gligorov, Joseph
- Azim, Hamdy A
Producer: 20190926
In:
The oncologist vol. 23
Availability: No items available.
|
|
20.
|
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). [electronic resource] by
- Azim, Hamdy A
- Omar, Ashraf
- Atef, Hesham
- Zawahry, Heba
- Shaker, Mohamed K
- Abdelmaksoud, Ah Kamel
- EzzElarab, Mohamed
- Abdel-Rahman, Omar
- Ismail, Mohamed
- Kassem, Loay
- Waked, Imam
Publication details: Journal of hepatocellular carcinoma 2018
In:
Journal of hepatocellular carcinoma vol. 5
Availability: No items available.
|